Schering-Plough layoffs
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough is cutting 110 jobs in New Jersey and 90 others across the country in an ongoing effort to reduce payroll by 10%. The company announced the layoffs after only 900 of 2,400 eligible employees elected to participate in a voluntary early retirement program. Sales representatives and other "customer-facing personnel," as well as employees working on the company's FDA consent decree obligations, were not affected by the cuts...
You may also be interested in...
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Recruitment for Schering-Plough's sales force expansion is 80% complete, Global Pharmaceutical President Carrie Cox told investors during a year-end conference call Jan. 26
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.